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The pattern of juvenile idiopathic arthritis; a retrospective Egyptian study 
 
INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is the most 
common chronic rheumatic disease in children.1, 2 It 
can be a serious and disabling condition 
complicated by joints destruction, growth 
disturbance, limb length discrepancy, osteoporosis 
and psychosocial problems.3 Juvenile idiopathic 
arthritis is not a single disease, but a term that 
encompasses all forms of arthritis that begins before 
16 years and persists for more than 6 weeks, and is 
of unknown origin.1, 2 It is thought to have both 
genetic and environmental components, triggering 
inflammation through immune-dysregulation which 
is associated with alterations in both humoral and 
cell mediated immunity. T lymphocytes have a 
central role, releasing pro-inflammatory cytokines 
(e.g., TNF-α, IL-6, and IL-1)4,5. It has hetero-
geneous presentation therefore, the International 
League of Associations for Rheumatology (ILAR) 
proposed different classification.3,6,7 The diagnosis 
of JIA is based upon the pattern of symptoms; 
morning stiffness (>1 hour), distribution of the 
inflamed joints and blood and x-ray findings and 
exclusion of other causes. While, the management 
of the disease is a multidisciplinary which rely on 
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anti-inflammatory and immune modulatory 
medications with physical therapy.3,8 The incidence, 
prevalence, clinical presentations vary among 
ethnic and geographically different population. Few 
Egyptian studies described the clinical profile of 
affected children which was our motivation to 
conduct this study in order to evaluate the clinical 
patterns of JIA, laboratory parameters and outcome 




This is an observational retrospective cross-
sectional study carried out at Alexandria University 
Children's hospital, Alexandria, Egypt. The current 
study was approved by local ethical committee of 
pediatric department and by the University 
Research Ethics Committee. All the medical 
records of the diagnosed JIA cases from January 
2004 till December 2010 were checked. The cases 
were diagnosed according to ILAR criteria and they 
were followed up more than 6 months at 
Rheumatology Clinic.6,7   
The collected data included: gender, age, age of 
first presentation, duration, clinical subtype 
(systemic onset arthritis, oligoarthritis or 
polyarthritis and arthralgia). The distribution of 
involved joints, main presenting features (morning 
stiffness, intermittent fever, skin rash, pallor, 
lymphadenopathy, hepato-splenomegaly, uveitis, 
pericardial effusion or valve damage). Results of 
laboratory data of CBC, CPR, erythrocyte 
sedimentation rate, rheumatoid factor (RF), 
antinuclear antibody (ANA). Results of Slit lamp 
examinations, chest x ray and echocardiography. 
Also, the study assessed different therapeutic 
protocols including: Single drug regimen 
(Prednisone, methotrexate or naproxen), double 
regimen (methotrexate with any of the previous 
drugs) and triple regimen as well as the outcome of 
disease whether remittent or unremittent. The 
disease course was considered remittent if disease 
activity lasted less than 2 years from the onset and 
terminated in remission without recurrence, while 
progressive or unremitting disease course was 
characterized by active disease for more than two 
years.9 
Pilot study: 
A pilot study was conducted. in order to fulfill the 
pilot study, a sample of 5 files of cases was chosen 
randomly. From the pilot study, the following 
points have been raised: 
a. The Pediatric Rheumatology Clinic of the 
Children’s Hospital, Alexandria University, was a 
suitable place for the research. 
b. The researcher can carry out data collection 
skillfully and with confidence. 
Analysis of data: 
The results were checked. Then, the data were 
entered into SPSS system files (SPSS package 
version 18) and the following statistical measures 
were used: Descriptive statistics, Kolmogorov-
Smirnov test, Kruskal Wallis test. Moreover, Chi-
Square test, Fisher's Exact test and Monte Carlo test 
were used to test for significance among qualitative 
variables. The significance of the results was at the 
5% level of significance. 
 
Statistical analysis 
Data was analyzed using the Statistical Program for 
Social Science (SPSS) version 18.0. Quantitative 
data was expressed as mean± standard deviation 
(SD). Qualitative data was expressed as frequency 
and percentage. Chi-square (X2) test was used to 
compare the proportions between two qualitative 
parameters. Independent-samples t-test was used to 




The current study included 63 patients with mean 
age of 7.3 y ±3.1 (ranged from 3.8y to 16 y) at 
study time however, the mean age at diagnosis was 
6.1±2.8 (ranged between 3 y and 14 y). About 
57.1% of the cases were from rural areas (mostly 
oligoarticular subtype) while 42.9% were from 
urban areas with highly significant differences to 
rural areas (p=0.018).  Positive family history of 
JIA was reported among 30.2% of cases as 
summarized in table (1). 
Table (2) showed the spectrum of clinical 
patterns of JIA in our study in which oligoarticular 
subtype were the predominant (41.2%) followed by 
polyarticular (35%) then systemic onset type in 
(23.8%) with no other subtypes. In oligoarticular 
onset JIA, 2 subtypes were detected, persistent 
oligoarticular arthritis, which was present in 77.0 % 
and extended oligoarticular arthritis which occurred 
in 33% of cases. 
The current study included 33 males and 30 
females, at 1.1:1 ratio. However, there was a female 
predominance in the oligoarticular (57.7%) and the 
systemic onset subtypes (53,4%) in comparison to 
polyarthritis which showed male predominance 
(68%) but with no significant difference. (tables 1, 
2) 
Table (3) showed the distribution of involved 
joints in different subtypes. Knee joint was the most 
frequently affected in oligoarticular subtype 
(84.3%) while wrist (86.4%) and ankle were mostly 
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encountered in the polyarticular and systemic onset 
respectively. The results showed highly significant 
difference between the studied subtypes as regards 
affection of the wrist joint (p=0.011), the elbow 
joint (p=<0.0001), cervical joint (p=0.001), 
sacroiliac joint (0.002), MTPS (p=0.014), PIPS 
(p=0.0002) and MCPS (p=<0.0001) in polyarticular 
type when compared to other subtypes. Meanwhile, 
no statistically significant differences in affection of 
the knee, the ankle, the hip and the shoulder joints 
between the subtypes.  
Regarding the clinical characteristics of 
children, table (3, 4) summarized that as it revealed 
highly significant difference between the studied 
subtypes as regards the intermittent fever 
(p=<0.0001), skin rash (p=<0.0001), 
lymphadenopathy (p=0.008), hepatosplenomegaly 
(p=0.008) and cardiac involvement (valve damage 
or pericardial effusion) (p=0.001) to systemic onset 
JIA rather than the other subtypes. While, the 
results showed no statistically significant 
differences regarding morning stiffness, pallor, 
uveitis, pleuritic, renal, skin, GIT involvements, 
oral and CNS disease between the three studied 
subtypes. 
Table (5) presented the results of main 
laboratory investigations. Anemia, leukocytosis, 
thrombocytopenia, elevated first hour ESR, and 
CRP were common finding at presentation but 
without significant difference among the subgroups. 
The results detected that the difference in raised 
second hour of ESR was significant high (p=0.018) 
in polyarticular type when compared to others. 
Also, difference in the percent of positive RF cases 
and ANA positive cases ((p=0.0001, p=0.007) were 
significantly higher in oligoarticular type.  
The difference in the percent of cases with 
positive RF was statistically significant higher 
among unremitting groups when compared to 
remitting group (p = 0.003). Meanwhile our results 
showed no statistically differences between 
remitting and unremitting groups as regards   
number of ANA positive cases as in table (6). 
Lastly, the outcome of the disease was displayed 
at table (1).  In general, disease remission was 
achieved among 30 cases out of 63 (47.4%) which 
were mostly (46.3%) among persistent 
oligoarthritis. Table (7) summarized the relation of 
remission to the drug regimen as it revealed that the 
difference in percent of remittent cases who were 
on tow drug regimen was statistical a significant 
higher (P=0.035*) when compared to single drug 
users (53.6% versus 20.1%).  However, no 
significant difference between remitted cases on 
















Gender       
Male  33 (52.4%) 7(46.6%) 11(42.3%) 15(68%) X2=3.46 
P=0.178 Female  30 (47.6%) 8(53.4%) 15(57.7%) 7(32%) 
Age (years)      
KWX2=2.694 
P=0.26 
Range  3.8-16 4-16 3-14 3-14 
Mean ± SD 7.3±3.1 6.9 ±2.9 11.13± 6.1 7.9±3.1 
Age at disease onset (years)      
KWX2=2.16 
P=0.34 
Range  3-14 3-14 3-12 3-12 
Mean ± SD 6.1±2.8 5.6±2.6 6.0±2.9 6.6±2.8 
Residence       
Urban  27(42.9%) 10 (66.7%) 6 (23.0%) 11(50.0%) X2=8.08 
P = 0.018* Rural  36 (57.1%) 5(33.3%) 20 (77.0%) 11(50.0%) 
Family history of JIA 19(30.2) 2 (13.3) 10(38.5) 7 (31.8) 
X2 = 2.896  
P = 0.408 
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Table 2. Presentation of JIA in pediatric clinic during the period from 2004 to 2010. 
Presentation at onset 
Course of disease 
Test of  
significance 
Total 
(n = 63) 
Remitting  
(n = 30) 
Unremitting 
(n = 33) 
No % No % 




2. Arthritis:      
A. Polyarthritis 10 33.3 12 36.4 22(35.0 %) 
B. Oligoarthritis: 14 46.7 12 36.4 26 (41.2%) 
 (n=14) (n=12) 
FEP=0.365 
 
І. Oligoarthritis to polyarthritis 2 14.2 4 33.3 6(23.0%) 
ІІ. Persistent oligoarthritis 12 85.8 8 66.7 20(77.0%) 




Yes 15 50.0 24 72.7 39(62.0%) 
No 15 50.0 9 36.3 24 (38.0%) 
X2: Chi-square test               KWX2: K*: Statistically significant at p ≤ 0.05  
 
 













No. % No. % No. % No. % 
Knee 8 53.3 22 84.6 17 77.3 X2=5.04 (0.080) 47 74.6 
Ankle 12 80 17 65.4 18 81.8 X2=2.0 (0.368) 47 74.6 
Wrist 11 73.3 12 46.2 19 86.4 X2=9.06 (0.011) * 42 66.7 
Hip 7 46.6 4 15.4 9 40.9 X2=5.61 (0.061) 20 31.7 
Shoulder 0 0.0 3 11.5 0 0.0 MCP=0.116 3 4.8 
Elbow 7 46.6 0 0.0 12 54.5 X2=19.38(<0.0001) * 19 30.2 
Cervical spine 0 0.0 0 0.0 7 31.8 MCP=0.001* 7 11.1 
Sacroiliac joint 0 0.0 0 0.0 6 27.3 MCP=0.002* 6 9.5 
MTPs 0 0.0 0 0.0 4 18.2 MCP=0.014* 4 6.3 
PIPs 7 46.6 2 7.7 14 63.6 X2=16.97 (0.0002) * 23 36.5 
MCPs 0 0.0 0 0.0 13 59 MCP=<0.0001* 13 20.6 
Pips: Proximal interphalangeal joints      MCPs: Metacarpophalangeal joints      
MTPS: Metatarsophalangeal joints.  X2: Chi-square test    MCP: Monte Carlo test    *significant at P≤0.05 
 
 
Table 4. Clinical characteristics in children according to onset of JIA  
Clinical characteristics 
SO-JIA  
(n = 15) 
Oligo-JIA 
(n = 26) 
Po-JIA 




(n = 63) 
No. % No. % No. % No. % 
Morning stiffness  10 66.7 17 65.4 15 68.2 X2=0.04 (P=0.979) 42 66.7 
Intermittent fever 12 80.0 1 3.8 3 13.6 MCP<0.0001* 16 25.4 
Skin rash 8 53.3 0 0.0 0 0.0 MCP<0.0001* 8 12.7 
Pallor 7 46.7 9 34.6 11 50.0 X2=1.27 (P=0.530) 27 42.9 
Lymphadenopathy 4 26.7 0 0.0 1 4.5 MCP=0.008* 5 7.9 
Hepato-splenomegaly 4 26.7 0 0.0 1 4.5 MCP=0.008* 5 7.9 
Uveitis 0 0.0 2 7.7 2 9.0 MCP=0.670 4 6.3 
Pleuritis 1 6.7 0 0.0 0 0.0 MCP=0.237 1 1.6 
Cardiac involvement 3 20.0 0 0.0 0 0.0 MCP=0.011* 3 4.8 
Renal involvement 1 6.7 0 0.0 1 4.5 MCP=0.503 2 3.2 
Skin involvement 3 20.0 1 3.8 1 4.5 MCP=0.203 5 7.9 
GIT involvement 4 26.7 1 3.8 1 4.5 MCP=0.067 6 9.5 
Oral diseases 1 6.7 1 3.8 1 4.5 MCP=1.000 3 4.8 
CNS diseases 2 13.3 0 0.0 1 4.5 MCP=0.106 3 4.8 
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Table 5. Laboratory parameters and results of investigations done to patients with different JIA subtypes. 
Laboratory parameters 












No. % No. % No. % No. % 
HB (<10 gm/dl) 11 50 9 34.6 7 46.6 X2=1.27 (0.53) 27 42.9 
WBCS (>13X103) 3 13.6 3 11.5 4 26.6 X2=1.76 (0.415) 10 15.9 
Platelets (<150x109) 6 27.2 7 26.9 8 53.3 X2=3.54 (0.169) 21 33.3 
CRP (positive results) 12 54.5 14 53.8 9 60 X2=0.16 (0.923) 35 55.6 
ESR 1st hour (>10mm/ hr.) 18 81.8 19 73 13 86.6 X2=1.2 (0.549) 50 79.4 
ESR 2nd hour (>15mm/ hr.) 20 90.9 14 53.8 11 73.3 X2=8.06 (0.018) * 45 71.4 
RF (positive results) 16 72.7 25 96.1 3 20 X2=26.32 (0.0001) * 44 69.8 
ANA (positive results) 3 13.6 10 38.5 0 0 MCP=0.007* 13 20.6 
Fundus examination +ve(uveitis) 2 9 2 7.7 0 0 MCP=0.447 4 6.3 
Chest X ray +ve findings 
(pneumonia±pleuritis) 
3 13.6 1 3.8 2 7 MCP=0.554 6 9.5 
X2: Chi-square test                                    MCP: Monte Carlo test                     *significant at P≤0.05 
 
 
Table 6. Relation between laboratory parameters (RF & ANA “positive cases”) and the course of the disease  
Laboratory Parameters  
course 










No % No % No    % 
RF (positive results) 15 50.0 29 87.9 FEp = 0.003* 44 69.8% 
ANA (positive results) 3 10.0 10 30.3 FEp = 0.064 13 20.6% 
FEp: p value for Fisher Exact test *: Statistically significant at p ≤0.05 
 
 
Table 7. Relation between the course (remitting and unremitting) of the disease and the treatment regimens. 
Types of drugs used 
course 







No % No % 
Single drug       
      Prednisone 2 6.7 4 12.1 FEP=0.674 6 (9.5%) 
      Methotrexate 2 6.7 6 18 FEP=0.261 8(12.7%) 
       Naproxen 2 6.7 1 3 FEP=0.601 3(4.8%) 
Shifting to combined drug regimen       
     Shifting to two drugs 16 53.2 9 27.3 X2=4.46 P=0.035* 25(39.7%) 
      Shifting to three drugs 8 26.7 13 39.6 X2=1.15 p=0.285 21(33.3%) 
FEP: Fisher's Exact test                 X2: Chi-Square test 
 
Table 8. The epidemiological data in the three Egyptian studies 
Variable Cairo study El Sharkia Alexandria 
(present study) 
No of cases 196 132 63 
M: F ratio 1:1.09 1:1.5 1.1:1 
Age of onset (Range) 6 m-12 y 4y-15 y 3 y-14y 
Age of onset (Mean) 6.25 y 10.5% 6.1y 
Rural to urban - 59.09% to 40.9% 57.1% to 42.9 
Positive family history 5.6% - 30.2% 
Percent of oligoarticular 41.3% 52.2 41.2% 
Percent of polyarticular 34.7% 29.2 35.0% 
Percent of systemic onset 24% 13.6 23.8% 
Uveitis   % 5.6 % 19.6% 6.3% 
Positive rheumatoid factor - 27.2% 69.8% 
Positive ANA % 18.9 % 48.5 % 20.6% 
Remission rate 46.9% - 47.4% 




Worldwide, Juvenile idiopathic arthritis (JIA) has a 
wide range of clinical presentations and outcomes.10 
It is characterized by chronic synovitis of peripheral 
joints manifested as soft tissue swelling and 
effusion. In the current study, medical records of 
sixty-three children at the pediatric rheumatology 
clinic were retrospectively analyzed. Similar to 
previous studies mainly in USA, Canada, Turkey, 
France and Spain oligoarticular JIA was found to be 
the most common clinical pattern.11,12 On contrary 
to Saudi Arabia study13, systemic onset was the 
most common type while a Kuwaiti study 
conducted by Khuffash14 in 2006 proved that there 
was an equal percentage between all subtypes.  
Moreover, our results matched previous Egyptian 
studies conducted in Cairo in 2009 and in El-
Sharkia in 2013 but with different frequencies from 
ours (41.3%, 52.2%, respectively) because of 
variability of environmental and genetic factors.15,16 
Most of the demographic data of the studied 
groups were consistent with results of previous 
national and international studies as the mean age 
of onset of the disease was (6.1±2.8 yr.), which was 
close to that reported in Saudi Arabia (6± 2 yr.) by 
Bahabri et al12 and Mengual et al17 in Spain (5.8±2.2 
yr.). Meanwhile, age was lower than that reported 
by Ruperto et al18 (8±3yr) and a cohort study at 
Taiwan (9.1y).19 Also, the current study reported 
that most of the cases were from rural areas similar 
to Quartier et al10 and Abu elsoud et al.16 Family 
history of JIA showed high frequency among 
patients like other studies.15, 20 On contrary, to many 
studies the numbers of male patients were higher 
than the females.11-16 However, our results matched 
Ozdogan et al21 and El-hemiari et al22 who reported 
male predominance. 
The Clinical profile of different subtypes of JIA 
was comparable to those reported in literature. knee 
joints were the predominately involved in 
oligoarticular JIA while wrist, elbow, sacroiliac 
joints and small joints of hand showed higher 
significant difference to poly articular subtype. 
Similar to the results reported by Viswanathakumar 
et al23 (Indian study). Our results were contradictory 
to Bahabri et al13 who concluded that knee joint was 
the least involved and this may be because the 
systemic onset subtype was the predominant type 
among Saudi children with common involvement of 
wrist or ankle joints. 
Despite that morning stiffness was the most 
common presenting symptom among all subtypes, 
fever, skin rash, lymphadenopathy, 
hepatosplenomegaly and cardiac involvement 
showed higher significant difference to systemic 
onset JIA group. This was agreed by Grassi et al,24 
Chandrasekaran et al25 and Salah et al.15 Our study 
reported that pallor was the predominant extra-
articular manifestations (42.2%). While Uveitis was 
manifested among (6.3%) of cases of oligoarticular 
and polyarticular subtypes. This was close to 
Ozdogan et al21, El-Hemiari et al22and Abu Elsoud 
et al16 (7%, 8.4% and 5.6%. respectively).  
Steinbrocker et al26 reported that incidence of 
uveitis among JIA patients in Western countries 
was ranging between 10% and 20%. In contrast to 
the results of Abdwani et al27 at 2015 (an Omani 
study) and Viswanathakumar et al23 (Indian study) 
who reported absent cases of uveitis. The great 
difference observed in uveitis incidence among 
patients with JIA could be attributed to many 
factors as difficulty in diagnosis, small sample sizes 
leading to larger variations in reported rates and 
may be close relation of uveitis and positive ANA 
titer. Concerning ANA, it was positive among 
20.6% of cases close to results of Gare et al28 and to 
Salah et al15 (18.4% and 19.9%). While others as 
Khuffash et al14 and Ozdogan et al21 reported lower 
results (12%, 5%) respectively. The higher 
percentage of positive ANA results could be 
attributed to higher incidence of infections inducing 
the illness. About 30.3% of ANA positive cases 
developed uveitis. Regarding other laboratory 
results, ESR was the most frequent raised 
laboratory result in all subgroups, followed by 
positive rheumatoid factor specially among 
oligoarticular subtype. Our results were nearly 
equal to those found in other studies.14, 20, 27 Most of 
anemic patients were of polyarticular subtype near 
to results of Baharbi et al.13Meanwhile, most of 
CRP positive cases were of systemic onset subtype 
as reported by Italian study done by Melano in 
2007.29 
The management of JIA aimed to control active 
symptoms, achieve remission and to prevent joint 
damage. Since the introduction of biologic agents 
such as methotrexate major advances has been 
achieved however, non-steroidal anti-inflammatory 
drugs (NSAIDs) are the mainstay of treatment. 
Glucocorticoids have been used usually for severe 
life-threatening disease, or rapidly progressive 
disease and uveitis. In the current study the patient 
outcomes and rate of remission were variable 
throughout the three subtypes.  
The current study showed global remission rate 
of 47.6% among all cases. Meanwhile, the highest 
remission rate was observed among patients 
suffering from oligoarthritis followed by 
polyarthritis and lastly among systemic onset cases. 
Similar to remission rates recorded by Salah et al15 
and Khufash et al14 (about 54%). Meanwhile, other 
studies reported lower rates (as 29.4%)13,21. This 
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variability in the relative frequency of the remission 
rate may be due to differences in environmental and 
genetic factors, with possible exposure to different 
types of infections and being subjected to different 
therapeutic regimens and or to the positivity of 
rheumatoid factor.30 
The highest remission rate (53.2%)was found 
among patients who received two drugs regimen. 
Similar remission rate was reported by many 
studies10, 14 specially Sircar et al31 (51%) however, 
Weiss et al had reported higher remission rate 
(79%).32 
Cases who used single drug regimen either 
prednisone or methotrexate and or naproxen 
showed lower remission rate (20.1%) in agreement 
to other studies.33 No significant difference of triple 
therapy to double therapy on the course of the 
disease matched to results found by Ozdogan et al 
and Quartier et al.10, 21 
Table (8) showed the epidemiological data in the 
three Egyptian studies - conducted in 3 




The characteristics of JIA in Egyptian children at 
different areas are comparable to each other with 
higher frequency of oligoarticular subtype disease 
specially for rural areas. The discrepancies between 
the pattern of the disease in Egypt and those 
reported from Arabian Gulf countries and Western 
countries may be related to different immunogenic 
background of different ethnic groups, a point that 
needs further studies.  
Future studies are necessary to clarify the role of 
other therapeutic alternatives in treatment and to 
elucidate the implications of different therapeutic 
regimens on long term morbidity and mortality. 
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